Skip to main content

Lilly Asia Ventures — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

102
Companies
$8.3B
Total invested
$103.5M
Avg. check
17
Industries
Biotechnology 18Health Care 14Medical 8Pharmaceutical 7Therapeutics 5Manufacturing 4+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 102
LavaMed
December 2022

LavaMed is a China based medical devices manufacturing company.

Enterprise · Suzhou$40.0M Series A
Lupeng Pharmaceutical
November 2022

Lupeng Pharmaceutical is a biotech company that focuses on the drug discovery and development of novel therapies for cancer treatment.

Biotechnology · Guangzhou$35.0M Series A
Neukio Biotherapeutics
September 2022

Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.

Biotechnology · Shanghai$50.0M Series A
Singlera Genomics
June 2022

Singlera Genomics is a fast growing company focusing on non-invasive genetic testing.

Biotechnology · La Jolla$44.9M Series B
Virtue Diagnostics
January 2022

Virtue Diagnostics is an innovative IVD company focused on infectious disease, cancer, and chronic diseases.

Health Care · Shanghai$100.0M Series B
Regor Therapeutics
December 2021

Regor Therapeutics is an international biotech company that focuses in the therapeutic areas of oncology, metabolic and autoimmune diseases.

Biotechnology · Boston$50.0M Series Unknown
Singleron Biotechnologies
November 2021

Singleron Biotechnologies is an innovative molecular diagnostic company.

Biotechnology · Nanjing$100.0M Series B
Hopstem
October 2021

Hopstem is a pharmaceutical company engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.

Biotechnology · Hangzhou$40.0M Series B
Scivita Medical Technology
August 2021

Scivita Medical Technology is focusing on the image processing R&D and technology innovation of endoscope.

Health Diagnostics · Suzhou$61.9M Series B
Zentera Therapeutics
August 2021

Zentera Therapeutics is a biopharmaceutical company.

Biotechnology · Shanghai$75.0M Series B
Duality Biologics
May 2021

Duality Biologics is a company focusing on the discovery, development and commercialization of new modality biologics to provide solutions.

Biopharma · Shanghai$90.0M Series B
Elpiscience Biopharmaceuticals
May 2021

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies

Biopharma · Shanghai$105.0M Series C
EdiGene
April 2021

EdiGene is a biotechnology company that develops genome editing technologies.

Biotechnology · Beijing$61.6M Series B
Fortis Therapeutics
March 2021

Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies against CD46.

Biotechnology · La Jolla$40.0M Series A
NovoCodex
March 2021

NovoCodex is a biopharmaceuticals company that specalizes in the business of genetic engineering, and cell culture.

Clinical Trials · Yuecheng$61.5M Series A
FutureGen
March 2021

FutureGen is a research and development manufacturer for antibody medication.

Biopharma · Changping$46.1M Series B
Passage Bio
January 2021

Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.

Biotechnology · Philadelphia$154.0M Post Ipo Equity
CARsgen Therapeutics
November 2020

CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor

Health Diagnostics · Shanghai$186.0M Series C
Turning Point Therapeutics
October 2020

Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.

Biotechnology · San Diego$460.0M Post Ipo Equity
InventisBio
September 2020

InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.

Biopharma · Shanghai$147.0M Series D
Magnolia NeuroSciences
July 2020

Magnolia NeuroSciences discovers and develops drug-like small molecule therapeutics for the prevention of neuronal cell death.

Biotechnology · New York$18.4M Series Unknown
ReadCoor
January 2020

Leader in true multi-omic spatial sequencing

Biotechnology · Cambridge$27.0M Series B
Peijia Medical
November 2019

Peijia Medical is an interventional medical products provider

Health Care · Nanjing$100.0M Series C
Tmunity Therapeutics
October 2019

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells.

Biotechnology · Philadelphia$75.0M Series B

Where Lilly Asia Ventures invests

Biotechnology18
Health Care14
Medical8
Pharmaceutical7
Therapeutics5
Manufacturing4

About Lilly Asia Ventures's portfolio

How many companies has Lilly Asia Ventures invested in?

Lilly Asia Ventures has invested in 102 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Lilly Asia Ventures invest in?

Lilly Asia Ventures's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 17 different industry categories.

What is Lilly Asia Ventures's largest investment?

Among tracked funding rounds, Turning Point Therapeutics received $460.0M in a Post Ipo Equity round. Lilly Asia Ventures's total known invested capital is $8.3B.

What is the average investment size for Lilly Asia Ventures?

Lilly Asia Ventures's average investment size is $103.5M across its portfolio of 102 companies.

What are Lilly Asia Ventures's most recent investments?

Recent Lilly Asia Ventures portfolio additions include LavaMed, Lupeng Pharmaceutical, Neukio Biotherapeutics, Singlera Genomics, Virtue Diagnostics. These companies were founded in 2020 or later.

Reach the founders behind these 102 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →